Abstract

Patients who underwent uneventful phacoemulsification over 15 months were randomly assigned to receive topical nepafenac (0.1%) [96 eyes], bromfenac (0.07%) [93], preservative‐free ketorolac (0.4%) [94], nepafenac (0.3%) [96], or prednisolone acetate (1%) [91 eyes].
At 1 and 6 weeks, there was no significant difference in pain score, conjunctival hyperemia, AC cells, change in IOP, and visual acuity between the prednisolone and the NSAIDs groups, though nepafenac 0.3% was most effective. At 6 weeks, there was no significant difference in the number of patients developing subclinical CME in the prednisolone versus NSAID group. The mean increase in CMT was significantly lower in nepafenac 0.3% than prednisolone at 1 and 6 weeks
NSAIDs used in isolation are comparable to prednisolone in preventing inflammation and pain after uneventful phacoemulsification. However, nepafenac 0.3% is most comparable to prednisolone and more efficacious in reducing the incidence of CME.